FDA Greenlights Ibuprofen Oral Suspension Compounding to Help With Hospital Supply
Increased demand for ibuprofen oral suspension products due to a surge in 3 circulating viruses prompted the Agency to issue compounding guidance.
Increased demand for ibuprofen oral suspension products due to a surge in 3 circulating viruses prompted the Agency to issue compounding guidance.
The 2022 CDC Clinical Practice Guideline is intended to help clinicians weigh the benefits and risks of opioids and alternative pain treatments for outpatients.
Iheezo is a sterile, preservative-free, single-patient use, ophthalmic gel preparation.
Posimir is a novel formulation of bupivacaine, an amide local anesthetic, designed to be administered directly into the surgical site.
The designation was based on data from two phase 2 proof-of-concept studies that evaluated VX-548 for acute pain following abdominoplasty or bunionectomy surgery.
SP-102 is a dexamethasone sodium phosphate viscous gel formulation that is administered by epidural injection.
The designation is supported by data from the phase 3 C.L.E.A.R. trial.
Zynrelef is a dual-acting local anesthetic that delivers a fixed-dose combination of bupivacaine and meloxicam.
Maxigesic is a combination of acetaminophen 1000mg and ibuprofen 300mg for IV infusion.
Zynrelef is a dual-acting local anesthetic that delivers a fixed-dose combination of bupivacaine, an amide local anesthetic, and meloxicam, an NSAID.